التفاصيل البيبلوغرافية
العنوان: |
The peptidic urotensin-II receptor ligand GSK248451 possesses less intrinsic activity than the low-efficacy partial agonists SB-710411 and urantide in native mammalian tissues and recombinant cell systems. |
المؤلفون: |
Behm, David J., Stankus, Gerald, Doe, Christopher P. A., Willette, Robert N., Sarau, Henry M., Foley, James J., Schmidt, Dulcie B., Nuthulaganti, Parvathi, Fornwald, James A., Ames, Robert S., Lambert, David G., Calo', Girolamo, Camarda, Valeria, Aiyar, Nambi V., Douglas, Stephen A. |
المصدر: |
British Journal of Pharmacology; May2006, Vol. 148 Issue 2, p173-190, 18p, 1 Diagram, 9 Charts, 11 Graphs |
مصطلحات موضوعية: |
ARTERIES, LIGANDS (Biochemistry), BIOLOGICAL assay, GENETIC transduction, PRIMATES, AORTIC diseases, LABORATORY rats |
مستخلص: |
Several peptidic urotensin-II (UT) receptor antagonists exert ‘paradoxical’ agonist activity in recombinant cell- and tissue-based bioassay systems, likely the result of differential urotensin-II receptor (UT receptor) signal transduction/coupling efficiency between assays. The present study has examined this phenomenon in mammalian arteries and recombinant UT-HEK (human embryonic kidney) cells.BacMam-mediated recombinant UT receptor upregulation in HEK cells augmented agonist activity for all four peptidic UT ligands studied. The nominal rank order of relative intrinsic efficacy was U-II>urantide ([Pen5-DTrp7-Orn8]hU-II4–11)>SB-710411 (Cpa-c[DCys-Pal-DTrp-Lys-Val-Cys]-Cpa-amide)≫GSK248451 (Cin-c[DCys-Pal-DTrp-Orn-Val-Cys]-His-amide) (the relative coupling efficiency of recombinant HEK cells was cat>human≫rat UT receptor).The present study further demonstrated that the use of high signal transduction/coupling efficiency isolated blood vessel assays (primate>cat arteries) is required in order to characterize UT receptor antagonism thoroughly. This cannot be attained simply by using the rat isolated aorta, an artery with low signal transduction/coupling efficiency in which low-efficacy agonists appear to function as antagonists.In contrast to the ‘low-efficacy agonists’ urantide and SB-710411, GSK248451 functioned as a potent UT receptor antagonist in all native isolated tissues studied (UT receptor selectivity was confirmed in the rat aorta). Further, GSK248451 exhibited an extremely low level of relative intrinsic activity in recombinant HEK cells (4–5-fold less than seen with urantide). Since GSK248451 (1 mg kg−1, i.v.) blocked the systemic pressor actions of exogenous U-II in the anaesthetized cat, it represents a suitable peptidic tool antagonist for delineating the role of U-II in the aetiology of mammalian cardiometabolic diseases.British Journal of Pharmacology (2006) 148, 173–190. doi:10.1038/sj.bjp.0706716; published online 20 March 2006 [ABSTRACT FROM AUTHOR] |
|
Copyright of British Journal of Pharmacology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
قاعدة البيانات: |
Complementary Index |